GemOx
GemOx or GEMOX is an acronym for one of the chemotherapy regimens used in the treatment of relapsed or primary refractory non-Hodgkin's lymphoma and Hodgkin's lymphoma.
When combined with Rituximab it is called R-GemOx, R-GEMOX or GemOx-R, GEMOX-R.
The [R]-GemOx regimen consists of:
- (R)ituximab - anti-CD20 monoclonal antibody that has the ability to kill both normal and malignant B cells;
- (Gem)citabine - an antimetabolite;
- (Ox)aliplatin - a platinum-based alkylating antineoplastic agent.[1][2]
Dosing regimen
| Drug | Dose | Mode | Days |
|---|---|---|---|
| (R)ituximab | 375 mg/m2 | IV infusion | Day 1 |
| (Gem)citabine | 1000 mg/m2 | IV infusion in 500 ml normal saline with the speed of 10 mg/m2/min | Day 2 |
| (Ox)aliplatin | 100 mg/m2 | IV infusion over 2hrs | Day 2 |
gollark: The CDC has a "disease of the week"?
gollark: Still, as koishi said, it probably won't be an issue here.
gollark: If, on other servers, there is a significant enough furry presence already that there's actually much of a "war", then you would expect that to have already triggered a war if that's all that's needed.
gollark: It, er, sounds like you stir up conflict somehow then?
gollark: > They'll make it as good as all the software they makeThis is Google. They will randomly kill it, or make another application doing nearly the same thing but lacking some critical feature and make everyone switch, while mining your data.
References
- GEMOX-R regimen is a highly effective salvage regimen in patients with refractory / relapsing diffuse large-cell lymphoma: a phase II study
- Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.